Item 7.01 Regulation FD Disclosure.

On September 10, 2022, Deciphera Pharmaceuticals, Inc. (the "Company") issued a press release announcing the presentation of initial clinical study results from the ongoing single agent dose escalation portion of the Company's Phase 1 study of DCC-3116, the Company's investigational inhibitor of ULK1/2, in patients with advanced or metastatic tumors with a mutant RAS or RAF gene, as an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. A copy of the DCC-3116 presentation at the ESMO Congress 2022 is posted on the Investors and News portion of the Company's website (www.deciphera.com) under "Events and Presentations".

On September 11, 2022, the Company issued a press release announcing the presentation of new clinical study results from the Phase 1 and Phase 2 portions of the Company's ongoing study of vimseltinib, the Company's investigational inhibitor of CSF1R, in patients with tenosynovial giant cell tumor not amenable to surgery, as two separate posters at the ESMO Congress 2022. A copy of the press release is being furnished as Exhibit 99.2 to this Current Report on Form 8-K. Copies of the Phase 1 and Phase 2 posters from the ESMO Congress 2022 are posted on the Investors and News portion of the Company's website (www.deciphera.com) under "Events and Presentations".

The information in this Current Report on Form 8-K (including Exhibits 99.1 and 99.2 attached hereto) is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



99.1      Press Release issued by Deciphera Pharmaceuticals, Inc. on September 10,
        2022

99.2      Press Release issued by Deciphera Pharmaceuticals, Inc. on September 11,
        2022

104     Cover Page Interactive Data File (embedded within the Inline XBRL
        document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses